Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: Ten-year outcome
Antineoplastic Combined Chemotherapy Protocols
Urinary Bladder Neoplasms
The majority of patients with invasive bladder tumors who achieve T0 status after neoadjuvant MVAC chemotherapy preserve their bladders for up to 10 years with bladder-sparing surgery. The bladder remains at risk for new invasive tumors. Cystectomy salvages the majority, but not all, of relapsing patients.